Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-11-05 DOI:10.1016/j.vaccine.2024.126497

Sung-a Kim , Megumi Maeda , Fumiko Murata , Haruhisa Fukuda

{"title":"Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study","authors":"Sung-a Kim , Megumi Maeda , Fumiko Murata , Haruhisa Fukuda","doi":"10.1016/j.vaccine.2024.126497","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Post-COVID-19 conditions have emerged as a global health challenge. This study examined the long-term effects of COVID-19 vaccination on the incidence and risk of post-COVID-19 conditions in Japan.</div></div><div><h3>Methods</h3><div>This retrospective cohort study was conducted using a database comprising medical claims, COVID-19 case information, and vaccination records of persons residing in four Japanese municipalities. The cohort included COVID-19 cases diagnosed between August 2020 and December 2022. Participants were classified according to the duration between their most recent COVID-19 vaccination and COVID-19 occurrence (≥365 days, 150–364 days, and 14–149 days). The incidences of 36 post-COVID-19 conditions were monitored for 3, 5, and 8 months after infection. Cox proportional hazards models were used to calculate the risk of developing each post-COVID-19 condition within 8 months after infection according to vaccination status.</div></div><div><h3>Results</h3><div>From among 84,464 participants, 9642 (11.4 %) developed post-COVID-19 conditions over 8 months. The 8-month risks of developing 28 (including various respiratory conditions, cardiovascular conditions, inflammatory and immune diseases, physical conditions, psychiatric conditions, and endocrine disorders) of the 36 target conditions were significantly lower when individuals had been recently vaccinated (14–149 days) before infection.</div></div><div><h3>Conclusions</h3><div>COVID-19 vaccination can reduce the incidence and risk of post-COVID-19 conditions if administered within 5 months before infection. Despite having the highest mean age and prevalence of comorbidities, individuals who were most recently vaccinated had a lower risk of developing post-COVID-19 conditions. These results provide important evidence for future COVID-19 vaccination strategies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126497"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24011794","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Post-COVID-19 conditions have emerged as a global health challenge. This study examined the long-term effects of COVID-19 vaccination on the incidence and risk of post-COVID-19 conditions in Japan.

Methods

This retrospective cohort study was conducted using a database comprising medical claims, COVID-19 case information, and vaccination records of persons residing in four Japanese municipalities. The cohort included COVID-19 cases diagnosed between August 2020 and December 2022. Participants were classified according to the duration between their most recent COVID-19 vaccination and COVID-19 occurrence (≥365 days, 150–364 days, and 14–149 days). The incidences of 36 post-COVID-19 conditions were monitored for 3, 5, and 8 months after infection. Cox proportional hazards models were used to calculate the risk of developing each post-COVID-19 condition within 8 months after infection according to vaccination status.

Results

From among 84,464 participants, 9642 (11.4 %) developed post-COVID-19 conditions over 8 months. The 8-month risks of developing 28 (including various respiratory conditions, cardiovascular conditions, inflammatory and immune diseases, physical conditions, psychiatric conditions, and endocrine disorders) of the 36 target conditions were significantly lower when individuals had been recently vaccinated (14–149 days) before infection.

Conclusions

COVID-19 vaccination can reduce the incidence and risk of post-COVID-19 conditions if administered within 5 months before infection. Despite having the highest mean age and prevalence of comorbidities, individuals who were most recently vaccinated had a lower risk of developing post-COVID-19 conditions. These results provide important evidence for future COVID-19 vaccination strategies.

查看原文本刊更多论文

接种 COVID-19 疫苗对罹患后 COVID 病症风险的影响：VENUS 研究

导言：COVID-19 后遗症已成为一项全球性的健康挑战。本研究探讨了 COVID-19 疫苗接种对日本 COVID-19 后遗症发病率和风险的长期影响。研究对象包括 2020 年 8 月至 2022 年 12 月期间确诊的 COVID-19 病例。根据最近一次接种COVID-19疫苗与COVID-19发生之间的持续时间对参与者进行了分类（≥365天、150-364天和14-149天）。在感染后的3、5和8个月中，对36种COVID-19后病症的发病率进行了监测。根据疫苗接种情况，使用 Cox 比例危险模型计算感染后 8 个月内出现每种 COVID-19 后疾病的风险。结果在 84,464 名参与者中，9642 人（11.4%）在 8 个月内出现了 COVID-19 后疾病。在感染前最近接种过疫苗（14-149 天）的人在 8 个月内患上 36 种目标疾病中的 28 种（包括各种呼吸系统疾病、心血管疾病、炎症和免疫疾病、身体疾病、精神疾病和内分泌失调）的风险显著较低。尽管平均年龄和合并症发病率最高，但最近接种过疫苗的人患 COVID-19 后遗症的风险较低。这些结果为未来的 COVID-19 疫苗接种策略提供了重要依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.